InvaTech Recalls Levocetirizine Dihydrochloride Tablets Due to Stability Failure
InvaTech Pharma Solutions is recalling specific lots of Levocetirizine Dihydrochloride Tablets 5 mg because one lot failed stability testing.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences. The issue is a stability testing failure without reported injuries.
Plain-English summary
InvaTech Pharma Solutions, LLC is recalling specific lots of Levocetirizine Dihydrochloride Tablets, USP, 5 mg 30-count bottles. The product is distributed by Marlex Pharmaceuticals, Inc. and is available nationwide in the USA.
The recall was initiated because one lot of the tablets failed stability testing, resulting in failed impurities or degradation specifications. The affected lots include Lot #051944A (Exp. April 2021), Lot #1119124 (Exp. October 2021), and Lot #062088 (Exp. June 2022).
Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product matches the recalled lots, it should be returned to the pharmacy or distributor for disposal or replacement.
The recalled product
- Product
- Levocetirizine Dihydrochloride Tablets, USP, 5 mg 30-count bottle, Rx Only, Distributed by: Marlex Pharmceuticals, Inc. New Castle, DE 19720. NDC 10135-0639-30
- Manufacturer
- InvaTech Pharma Solutions, LLC
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: 051944A Exp. Date April - 2021
- 1119124 Exp Date Oct - 2021
- 062088 Exp Date June - 2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24